Sosei, HRA, and Sandoz/Hexal Australia to Conclude Sublicensing Agreement for "Morning After Pill" SOH-075.Tokyo, Japan, Dec 21, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Japanese biopharmaceutical company Sosei has announced that it and French pharmaceutical Laboratoire HRA HRA Health Reimbursement Arrangement HRA Health Risk Assessment HRA Housing and Redevelopment Authority HRA Human Resources Administration HRA Health Reimbursement Account HRA Housing Revenue Account Pharma (HRA) have entered into a sublicensing agreement with Sandoz/Hexal Australia, a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Novartis AG, for the distribution of SOH-075, an oral levonorgestrel levonorgestrel /le·vo·nor·ges·trel/ (-nor-jes´trel) the levorotatory form of norgestrel; used as an oral or subdermal contraceptive. le·vo·nor·ges·trel n. emergency contraceptive developed by HRA. Under the agreement terms, Sandoz Hexal will be licensed to distribute SOH-075 in Australia. Orally administered within 72 hours after an unprotected sexual intercourse, the drug can prevent pregnancy. The agent is currently marketed in 60 countries worldwide, including France, Italy, South Korea and Taiwan, under the trade name of Norlevo. In April 2001, Sosei has concluded a marketing agreement with HRA whereby Sosei can exclusively sell SOH-075 in Japan, Australia and New Zealand. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion